News - FAIS Africa - Page 113

September 9, 2021 | Ad26.CoV2.S vaccine significantly boosts pre-existing SARS-CoV-2 specific antibodies but not CD4 T cell immune responses | Immunopaedia.org.za

Ad26.CoV2.S vaccine significantly boosts pre-existing SARS-CoV-2 specific antibodies but not CD4 T cell immune responses

Immunology research update from www.immunopaedia.org.za. COVID-19 vaccines are provided to all individuals, regardless of previous SARS-CoV-2 infection. We have previously highlighted research findings that showed vaccination with BNT162b2 (Pfizer/BioNTech) significantly boosts pre-existing SARS-CoV-2 immunity induced by natural infection (Read more: Antibody response to vaccination post-COVID-19 infection). Is this boosting effect observed in individuals vaccinated with other COVID-19 vaccines? Ad26.COV2.S vaccine, single-dose adenovirus 26 vectored vaccine expressing the SARS-CoV-2 Wuhan-1 stabilized spike (S) protein, is highly effective against the development of severe COVID-19 was…

September 6, 2021 | A potential new biomarker for Preeclampsia | Immunopaedia.org.za

A potential new biomarker for Preeclampsia

Immunology research update from www.immunopaedia.org.za. Preeclampsia (PE) is a devastating disorder which effects more than 3-5% of pregnancies worldwide and remains to be one of the leading causes of global maternal and perinatal mortality and morbidity. These deaths are even more prevalent in middle to lower income countries. PE is a common disorder of pregnancy presenting clinically with hypertension and proteinuria. The placenta plays a significant role in determining the clinical presentation of the disease due to a number of factors…

September 1, 2021 | Reprogramming the Tumour Microenvironment – Improving Cancer Survival | Immunopaedia.org.za

Reprogramming the Tumour Microenvironment – Improving Cancer Survival

Immunology research update from www.immunopaedia.org.za. Cancer, a disease effecting every population in the world, consistently challenges researchers and clinicians into creating innovative treatments and therapeutic approaches. Claiming the lives of approximately 600,000 people in the United States’ of America alone, new therapeutics are needed to combat this destructive disease. Immunotherapy targeting of immune checkpoints, a relatively new field of cancer treatment, has shown to achieve consistent and favourable responses across several tumour types. However, this benefit does not always clinically translate…

August 27, 2021 | Does B.1.351 SARS-CoV-2 variant escape T cell immune responses? | Immunopaedia.org.za

Does B.1.351 SARS-CoV-2 variant escape T cell immune responses?

Immunology research update from www.immunopaedia.org.za. The majority of our knowledge of how pre-existing SARS-CoV-2 immunity induced by infection or vaccination responds to emerging SARS-CoV-2 variants of concern (VOC) has largely focused on the neutralisation capacity of antibodies. These studies demonstrated that SARS-CoV-2 VOCs can partially overcome pre-existing immunity resulting in infection despite robust immune responses. (Read more: Do mutations in SARS-CoV-2 variants reduce the functional activity of mRNA-vaccine elicited Abs?, Mutations in SARS-Cov-2 B.1.351 variant reduces vaccine induced Ab neutralisation ). However, many…

August 20, 2021 | Neutrophil dominance leads to protection from P. falciparum blood-stage merozoites | Immunopaedia.org.za

Neutrophil dominance leads to protection from P. falciparum blood-stage merozoites

Immunology research update from Immunopaedia.org.za Malaria manifests and develops its clinical phenotype following blood-stage Plasmodium falciparum infection. Intraerythrocytic replication of asexual parasites and release of free merozoites (offspring parasites) into circulation further characterises this infection which leads to invasion new erythrocytes. Free merozoites may be an interesting target for therapeutics due to the fact that they have an increased vulnerability to various defence mechanisms/factors of the host including: immune factors, including antibodies, complement, and leukocytes. It is known that passive transfer of IgG antibodies…

August 19, 2021 | A novel pathway of immune and host cell evasion by Mycobacterium tuberculosis | Immunopaedia.org.za

A novel pathway of immune and host cell evasion by Mycobacterium tuberculosis

Immunology research update from Immunopaedia.org.za.  Mycobacterium tuberculosis (Mtb), is a pathogenic organism causing infection and a disease phenotype which results in millions of deaths per year. Despite what is known about this organism, researchers and clinicians are still looking for answers as to how this ingenious pathogen evades the host immune response and adapts to its human host, leading to subsequent infection. It is known that immune cells of the host take up Mtb through phagocytosis, however Mtb persists through several mechanisms of…

1 111 112 113 114 115 119